Somewhat Positive Media Coverage Somewhat Unlikely to Affect ZIOPHARM Oncology (ZIOP) Share Price

News headlines about ZIOPHARM Oncology (NASDAQ:ZIOP) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ZIOPHARM Oncology earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 47.0825691412309 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the media headlines that may have impacted Accern’s rankings:

Several equities research analysts have commented on ZIOP shares. Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, April 26th. HC Wainwright started coverage on ZIOPHARM Oncology in a report on Thursday, June 1st. They issued a “buy” rating and a $9.50 target price on the stock. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $13.17.

Shares of ZIOPHARM Oncology (NASDAQ ZIOP) traded up 1.10% on Friday, hitting $5.51. The stock had a trading volume of 1,532,563 shares. The company’s 50 day moving average price is $5.93 and its 200-day moving average price is $6.33. The company’s market cap is $774.88 million. ZIOPHARM Oncology has a 12 month low of $4.84 and a 12 month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to analysts’ expectations of $1.66 million. During the same quarter last year, the firm earned ($1.01) earnings per share. The firm’s quarterly revenue was down 5.9% compared to the same quarter last year. On average, analysts expect that ZIOPHARM Oncology will post ($0.54) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Insider Buying and Selling by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

What are top analysts saying about ZIOPHARM Oncology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ZIOPHARM Oncology Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit